Amylin slashes sales force by 35%

Share this article:
Amylin slashes sales force by 35%
Amylin slashes sales force by 35%
Amylin is cutting 200 sales positions -- around 35% of its sales force -- as it merges its specialty and primary care sales forces into a single organization targeting endocrinologists and diabetes-focused primary care physicians.

The company, which co-markets Byetta (exenatide) with Lilly, will field a reduced sales force of 325 reps and expects to save $45 million in 2010 from the realignment. Lilly reps will continue to detail endocrinologists and primary care physicians more broadly on Byetta injection, and the move “will better position the companies for the launch of exenatide once weekly,” Amylin said. Lilly, Amylin and Alkermes announced today that they have filed an NDA for a weekly version of the drug for type 2 diabetes.
  
“These changes build on Amylin's scientific strength, and leverage Lilly's expertise and reach with primary care prescribers, so that we are well positioned to address the information needs of the complex diabetes market,” said Amylin president and CEO Daniel Bradbury. “Today's actions are in line with our stated goal of achieving positive operating cash flow by the end of 2010 while continuing to position the company to increase sales of Byetta and Symlin and bring exenatide once weekly to market as quickly as possible.”

In November, the San Diego-based firm announced plans to cut 325 positions at its headquarters amid worries about Byetta side effects, and it has been engaged in a proxy battle with corporate raider Carl Icahn and other major investors.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...